April 22–24, 2021
Tune into this scientific talk by Dr. Michal Besser and hear about the importance of on-site CAR T cell production. Learn from her experiences with over 200 CAR T cell procedures perfomed and find out which tools help her to streamline QC assays and patient monitoring.
The presentation will focus on:
• comparison of CD19 CAR T cell production for NHL and ALL patients
• advantages of on-site CAR T production
• QC requirements for on-site CAR T production
Sheba Medical Center, Israel
Michal Besser, Ph.D. is the head of laboratory at The Ella Lemelbaum Institute for Immuno-Oncology and the scientific director of the ABC GMP facility at the Sheba Medical Center in Israel. Dr. Besser is an Assistant Professor at the Department of Clinical Immunology and Microbiology at Tel Aviv University. She completed her undergraduate studies and Ph.D. at the University of Munich, Germany, and her postdoctoral research at the Weizmann Institute of Science, Israel. The Besser lab is specialized in the clinical production of CAR T cells and Tumor Infiltrating Lymphocytes (TIL) for therapy of cancer patients. Adoptive cell therapy serves as a platform for a wide range of research projects, which mainly seek the understanding and improvement of cellular therapies and immunotherapy.